Economic end points in phase II trials.
Publication
, Journal Article
Mark, DB; Simons, TA
Published in: Am Heart J
April 2000
Duke Scholars
Published In
Am Heart J
DOI
ISSN
0002-8703
Publication Date
April 2000
Volume
139
Issue
4
Start / End Page
S155 / S157
Location
United States
Related Subject Headings
- Treatment Outcome
- Humans
- Cost-Benefit Analysis
- Clinical Trials, Phase II as Topic
- Cardiovascular System & Hematology
- Cardiovascular Agents
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Mark, D. B., & Simons, T. A. (2000). Economic end points in phase II trials. Am Heart J, 139(4), S155–S157. https://doi.org/10.1016/s0002-8703(00)90063-2
Mark, D. B., and T. A. Simons. “Economic end points in phase II trials.” Am Heart J 139, no. 4 (April 2000): S155–57. https://doi.org/10.1016/s0002-8703(00)90063-2.
Mark DB, Simons TA. Economic end points in phase II trials. Am Heart J. 2000 Apr;139(4):S155–7.
Mark, D. B., and T. A. Simons. “Economic end points in phase II trials.” Am Heart J, vol. 139, no. 4, Apr. 2000, pp. S155–57. Pubmed, doi:10.1016/s0002-8703(00)90063-2.
Mark DB, Simons TA. Economic end points in phase II trials. Am Heart J. 2000 Apr;139(4):S155–S157.
Published In
Am Heart J
DOI
ISSN
0002-8703
Publication Date
April 2000
Volume
139
Issue
4
Start / End Page
S155 / S157
Location
United States
Related Subject Headings
- Treatment Outcome
- Humans
- Cost-Benefit Analysis
- Clinical Trials, Phase II as Topic
- Cardiovascular System & Hematology
- Cardiovascular Agents
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services
- 1102 Cardiorespiratory Medicine and Haematology